476 related articles for article (PubMed ID: 25365870)
1. [Molecular mechanisms of action of bisphosphonates and strontium ranelate].
Vengerovskiĭ AI; Khlusov IA; Nechaev KA
Eksp Klin Farmakol; 2014; 77(9):43-6. PubMed ID: 25365870
[TBL] [Abstract][Full Text] [Related]
2. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
[TBL] [Abstract][Full Text] [Related]
3. [The combined use of bisphosphonates and strontium ranelate with osseosubstituting materials].
Khlusov IA; Vengerovsky AI; Novitsky VV
Vestn Ross Akad Med Nauk; 2014; (11-12):128-32. PubMed ID: 25971138
[TBL] [Abstract][Full Text] [Related]
4. Assessment of OPG/RANK/RANKL gene expression levels in peripheral blood mononuclear cells (PBMC) after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis.
Stuss M; Rieske P; Cegłowska A; Stêpień-Kłos W; Liberski PP; Brzeziańska E; Sewerynek E
J Clin Endocrinol Metab; 2013 May; 98(5):E1007-11. PubMed ID: 23543663
[TBL] [Abstract][Full Text] [Related]
5. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
6. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
Liu W; Zhang X
Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
[TBL] [Abstract][Full Text] [Related]
7. Strontium ranelate inhibits key factors affecting bone remodeling in human osteoarthritic subchondral bone osteoblasts.
Tat SK; Pelletier JP; Mineau F; Caron J; Martel-Pelletier J
Bone; 2011 Sep; 49(3):559-67. PubMed ID: 21700005
[TBL] [Abstract][Full Text] [Related]
8. Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions.
Fioramonti M; Santini D; Iuliani M; Ribelli G; Manca P; Papapietro N; Spiezia F; Vincenzi B; Denaro V; Russo A; Tonini G; Pantano F
Oncotarget; 2017 Mar; 8(12):20113-20121. PubMed ID: 28223547
[TBL] [Abstract][Full Text] [Related]
9. The roles of TNFR1 in lipopolysaccharide-induced bone loss: dual effects of TNFR1 on bone metabolism via osteoclastogenesis and osteoblast survival.
Ochi H; Hara Y; Tagawa M; Shinomiya K; Asou Y
J Orthop Res; 2010 May; 28(5):657-63. PubMed ID: 19890995
[TBL] [Abstract][Full Text] [Related]
10. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
[TBL] [Abstract][Full Text] [Related]
11. Osteoblasts play key roles in the mechanisms of action of strontium ranelate.
Brennan TC; Rybchyn MS; Green W; Atwa S; Conigrave AD; Mason RS
Br J Pharmacol; 2009 Aug; 157(7):1291-300. PubMed ID: 19563530
[TBL] [Abstract][Full Text] [Related]
12. [Control of bone resorption by RANKL-RANK system].
Harada S; Takahashi N
Clin Calcium; 2011 Aug; 21(8):1121-30. PubMed ID: 21814016
[TBL] [Abstract][Full Text] [Related]
13. Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss.
Trouvin AP; Goëb V
Clin Interv Aging; 2010 Nov; 5():345-54. PubMed ID: 21228900
[TBL] [Abstract][Full Text] [Related]
14. [Melatonin and bone status].
Ostrowska Z; Wołkowska-Pokrywa K; Kos-Kudła B; Swietochowska E; Marek B; Kajdaniuk D
Pol Merkur Lekarski; 2006 Oct; 21(124):389-93. PubMed ID: 17205785
[TBL] [Abstract][Full Text] [Related]
15. [The OPG/RANKL/RANK system and bone resorptive disease].
Liu JZ; Ji ZL; Chen SM
Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):655-60. PubMed ID: 15971575
[TBL] [Abstract][Full Text] [Related]
16. What is the rank of RANKL in spondylarthritis?
Loddenkemper K; Burmester GR
Arthritis Rheum; 2008 Mar; 58(3):641-4. PubMed ID: 18311809
[No Abstract] [Full Text] [Related]
17. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation.
Vandooren B; Cantaert T; Noordenbos T; Tak PP; Baeten D
Arthritis Rheum; 2008 Mar; 58(3):718-29. PubMed ID: 18311801
[TBL] [Abstract][Full Text] [Related]
18. Osteoprotegerin deficiency attenuates strontium-mediated inhibition of osteoclastogenesis and bone resorption.
Peng S; Liu XS; Zhou G; Li Z; Luk KD; Guo XE; Lu WW
J Bone Miner Res; 2011 Jun; 26(6):1272-82. PubMed ID: 21611968
[TBL] [Abstract][Full Text] [Related]
19. Raloxifene inhibits bone loss and improves bone strength through an Opg-independent mechanism.
Yan MZ; Xu Y; Gong YX; Liu JM; Lu SY; Huang L; Wang ZG; Zhao YJ; Pang XF
Endocrine; 2010 Feb; 37(1):55-61. PubMed ID: 20963556
[TBL] [Abstract][Full Text] [Related]
20. Effects of dietary calcium to available phosphorus ratios on bone metabolism and osteoclast activity of the OPG /RANK/RANKL signalling pathway in piglets.
Zhao L; Li M; Sun H
J Anim Physiol Anim Nutr (Berl); 2019 Jul; 103(4):1224-1232. PubMed ID: 31062421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
